ReN 1820

Drug Profile

ReN 1820

Alternative Names: TrkAd5

Latest Information Update: 21 Jul 2006

Price : $50

At a glance

  • Originator University of Bristol
  • Developer ReNeuron
  • Class Anti-inflammatories
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation; Interstitial cystitis

Most Recent Events

  • 21 Jul 2006 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)
  • 21 Jul 2006 Discontinued - Preclinical for Interstitial cystitis in United Kingdom (unspecified route)
  • 21 Jul 2006 ReN 1820 is available for outlicensing (http://www.reneuron.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top